Mantle cell lymphoma.

[1]  A. Santoro,et al.  Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL) , 2018, Blood.

[2]  Sonali M. Smith,et al.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. , 2018, Blood.

[3]  L. Kristensen,et al.  Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy , 2018, International journal of molecular sciences.

[4]  Michael L. Wang,et al.  Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL) , 2018, British journal of haematology.

[5]  E. Campo,et al.  Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. , 2018, Blood.

[6]  S. Lade,et al.  Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma , 2018, The New England journal of medicine.

[7]  K. Grønbæk,et al.  Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Haematology.

[8]  M. Boccadoro,et al.  HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data , 2017, BMC Bioinformatics.

[9]  R. Gascoyne,et al.  Observation as the initial management strategy in patients with mantle cell lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Houot,et al.  Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma , 2017, The New England journal of medicine.

[11]  E. Campo,et al.  SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. , 2017, Blood.

[12]  B. Sander,et al.  Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. , 2017, The American journal of pathology.

[13]  G. Follows,et al.  Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi‐centre case series from the United Kingdom , 2017, British journal of haematology.

[14]  O. Casasnovas,et al.  OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL , 2017 .

[15]  F. Turturro,et al.  IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO , 2017 .

[16]  T. Kipps,et al.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Leonard,et al.  A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma , 2016 .

[18]  S. Pileri,et al.  Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi , 2016 .

[19]  Michael L. Wang,et al.  Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study , 2016 .

[20]  KyungMann Kim,et al.  Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study , 2016 .

[21]  E. Giné,et al.  Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. , 2016, Cancer cell.

[22]  A. Rosenwald,et al.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Belayachi,et al.  Efficacy of the GemOx‐R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma , 2016, British journal of haematology.

[24]  W. Klapper,et al.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.

[25]  A. Jemal,et al.  Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma , 2016, Cancer.

[26]  W. Wilson,et al.  Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. , 2016, Blood.

[27]  E. Campo,et al.  SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6 , 2016, Leukemia.

[28]  J. Burke,et al.  Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. , 2016, Clinical lymphoma, myeloma & leukemia.

[29]  R. Advani,et al.  Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.

[30]  Delong Liu,et al.  SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma , 2016, Biomarker Research.

[31]  J. Radford,et al.  Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. , 2016, The Lancet. Oncology.

[32]  T. Vogl,et al.  Cutaneous involvement as a rare first sign of systemic mantle cell lymphoma: A case report and review of the literature , 2016, Molecular and clinical oncology.

[33]  J. Goldberg,et al.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.

[34]  G. Follows,et al.  The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial , 2016, Haematologica.

[35]  Sonali M. Smith,et al.  Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601 , 2016, British journal of haematology.

[36]  Michael L. Wang,et al.  Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center , 2016, British journal of haematology.

[37]  P. Zinzani,et al.  The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL) , 2015 .

[38]  R. Gressin,et al.  Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group , 2015 .

[39]  Sonali M. Smith,et al.  Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. , 2015, The New England journal of medicine.

[40]  M. Boccadoro,et al.  Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. , 2015, The Journal of molecular diagnostics : JMD.

[41]  S. Beriwal,et al.  Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm. , 2015, International journal of radiation oncology, biology, physics.

[42]  E. Giné,et al.  Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype , 2015, Modern Pathology.

[43]  K. Ru,et al.  High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival , 2015, Oncotarget.

[44]  P. Hari,et al.  Long‐term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning , 2015, Cancer.

[45]  A. Onitilo,et al.  A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study , 2015, Cancer.

[46]  S. Mourah,et al.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. , 2015, Blood.

[47]  R. Suzuki,et al.  Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan , 2015, British journal of haematology.

[48]  J. Cerhan,et al.  Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 , 2015, American journal of hematology.

[49]  Michael L. Wang,et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.

[50]  J. Vose.  Mantle cell lymphoma: 2015 update on diagnosis, risk‐stratification, and clinical management , 2015, American journal of hematology.

[51]  W. Klapper,et al.  High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. , 2015, Blood.

[52]  A. Zelenetz,et al.  Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era , 2015, Bone Marrow Transplantation.

[53]  D. Chihara,et al.  Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  S. Ferrero,et al.  Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience , 2015, Haematologica.

[55]  S. Nakamura,et al.  Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  J. Delabie,et al.  miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. , 2015, Blood.

[57]  B. Coiffier,et al.  Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis , 2015, Experimental Hematology & Oncology.

[58]  A. LaCasce,et al.  Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501) , 2015, Leukemia & lymphoma.

[59]  Alexandra G. Smith,et al.  Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network , 2015, British Journal of Cancer.

[60]  W. Klapper,et al.  Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma , 2015, Leukemia.

[61]  F. Cavalli,et al.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. , 2015, The New England journal of medicine.

[62]  N. Schmitz,et al.  Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study , 2015, British journal of haematology.

[63]  Jeffery A. Jones,et al.  A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. , 2015, Blood.

[64]  E. Hoster,et al.  MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network , 2014 .

[65]  Michael L. Wang,et al.  Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy , 2014 .

[66]  Su-Jin Shin,et al.  Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour‐associated macrophages , 2014, Hematological oncology.

[67]  Shuangge Ma,et al.  Racial differences in mantle cell lymphoma in the United States , 2014, BMC Cancer.

[68]  E. Campo,et al.  SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. , 2014, Blood.

[69]  T. Witzig,et al.  Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  P. Mehta,et al.  Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database. , 2014, Clinical lymphoma, myeloma & leukemia.

[71]  J. Byrd,et al.  Non-Hodgkin's lymphomas, version 4.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[72]  I. Lossos,et al.  Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14. , 2014, Annals of Diagnostic Pathology.

[73]  E. Kimby,et al.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma , 2014, Leukemia.

[74]  A. Palumbo,et al.  Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders , 2014, Leukemia.

[75]  J. Byrd,et al.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). , 2014, Blood.

[76]  J. Burke,et al.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.

[77]  E. Kimby,et al.  Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. , 2014, Blood.

[78]  W. Stevens,et al.  Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  Michael L. Wang,et al.  Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study , 2014, British journal of haematology.

[80]  M. Dyer,et al.  Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma – a phase II trial , 2014, British Journal of Haematology.

[81]  G. Behre,et al.  Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO) , 2014, Annals of Hematology.

[82]  C. Panizo,et al.  Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience , 2014, Annals of Hematology.

[83]  C. Leux,et al.  Mantle cell lymphoma epidemiology: a population-based study in France , 2014, Annals of Hematology.

[84]  H. Tagawa,et al.  Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma , 2014, Oncogene.

[85]  J. Armitage,et al.  Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. , 2014, Biology of Blood and Marrow Transplantation.

[86]  J. Delabie,et al.  SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study , 2014, British journal of haematology.

[87]  M. Berger,et al.  A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma , 2014, Leukemia & lymphoma.

[88]  Shuangge Ma,et al.  Risk factors for etiology and prognosis of mantle cell lymphoma , 2014, Expert review of hematology.

[89]  J. Kolitz,et al.  Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature. , 2014, International journal of clinical and experimental pathology.

[90]  S. Montoto,et al.  Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  A. Nagler,et al.  Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma? , 2014, Leukemia & lymphoma.

[92]  F. d'Amore,et al.  Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. , 2013, Blood.

[93]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[94]  J. Drach,et al.  Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  A. Salar,et al.  First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group , 2013, Haematologica.

[96]  Jeffrey A Jones,et al.  Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma , 2013, Bone Marrow Transplantation.

[97]  G. Salles,et al.  Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  L. Waldron,et al.  MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[100]  J. Szer,et al.  Prognostic impact of monocyte count at presentation in mantle cell lymphoma , 2013, British journal of haematology.

[101]  E. Giné,et al.  Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  J. Drach,et al.  Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma , 2013, Journal of Cancer Research and Clinical Oncology.

[103]  C. Doglioni,et al.  A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma. , 2013, The oncologist.

[104]  M. Boccadoro,et al.  Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma , 2013, Annals of Hematology.

[105]  L. Rimsza,et al.  A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  J. Leonard,et al.  Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). , 2013 .

[107]  A. Rosenwald,et al.  microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics , 2013, Clinical Cancer Research.

[108]  Richard A. Moore,et al.  The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. , 2013, Blood.

[109]  C. Flowers,et al.  Using primary site as a predictor of survival in mantle cell lymphoma , 2013, Cancer.

[110]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[111]  N. Schmitz,et al.  ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  P. Hari,et al.  Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[113]  E. Campo,et al.  SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. , 2013, Blood.

[114]  W. Klapper,et al.  Lymphoma ‘type K.’—in memory of Karl Lennert (1921–2012) , 2013, Leukemia.

[115]  A. Rosenwald,et al.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. , 2013, Blood.

[116]  G. Pizzolo,et al.  Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  R. Tsang,et al.  Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital , 2013, Leukemia & lymphoma.

[118]  Sonali M. Smith,et al.  An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA , 2013, Leukemia & lymphoma.

[119]  W. Wilson,et al.  Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma , 2012 .

[120]  I. Flinn,et al.  Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial. , 2012 .

[121]  G. Cook,et al.  Guidelines for the investigation and management of mantle cell lymphoma , 2012, British journal of haematology.

[122]  E. Giné,et al.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.

[123]  L. Colomo,et al.  SOX11 is useful in differentiating cyclin D1‐positive diffuse large B‐cell lymphoma from mantle cell lymphoma , 2012, Histopathology.

[124]  E. Campo,et al.  Molecular pathogenesis of mantle cell lymphoma. , 2012, The Journal of clinical investigation.

[125]  R. Advani,et al.  Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  W. Klapper,et al.  Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.

[127]  E. Kimby,et al.  Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.

[128]  Lauren B. Smith,et al.  Transformation of indolent mantle cell lymphoma to pleomorphic mantle cell lymphoma: case report and review of clinical and morphologic variants. , 2012, Archives of pathology & laboratory medicine.

[129]  A. Goy,et al.  Post‐treatment (not interim) positron emission tomography‐computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R‐HyperCVAD , 2012, Cancer.

[130]  B. Shah,et al.  Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[131]  P. Mclaughlin,et al.  Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.

[132]  M. Ghielmini,et al.  A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma , 2012, Haematologica.

[133]  R. Houot,et al.  Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[134]  L. Staudt,et al.  Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. , 2012, Blood.

[135]  L. Staudt,et al.  The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation , 2012, Leukemia.

[136]  B. Cheson,et al.  Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 , 2012, Haematologica.

[137]  E. Giné,et al.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.

[138]  S. Pileri,et al.  Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers , 2012, Haematologica.

[139]  L. Gordon,et al.  Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. , 2012, Blood.

[140]  A. Ivanova,et al.  A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma , 2012, Leukemia & lymphoma.

[141]  R. Warnke,et al.  In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior , 2012, Haematologica.

[142]  F. Angrilli,et al.  Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi , 2012, British journal of haematology.

[143]  F. Rodeghiero,et al.  The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. , 2012, Blood cells, molecules & diseases.

[144]  S. Gardiner,et al.  Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007 , 2012, Leukemia & lymphoma.

[145]  C. Carlo-Stella,et al.  Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study , 2011 .

[146]  H. Hjalgrim,et al.  Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. , 2011, Seminars in cancer biology.

[147]  J. C. Eickhoff,et al.  VcR‐CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study , 2011, British journal of haematology.

[148]  Ash A. Alizadeh,et al.  Utility of positron emission tomography scans in mantle cell lymphoma , 2011, American journal of hematology.

[149]  A. Rosenwald,et al.  Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. , 2011, Blood.

[150]  K. Ohshima,et al.  Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki‐67 index , 2011, Cancer Science.

[151]  J. Eickhoff,et al.  Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network , 2011, Leukemia & lymphoma.

[152]  D. Maloney,et al.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  T. Witzig,et al.  Initial therapy of mantle cell lymphoma , 2011, Therapeutic advances in hematology.

[154]  I. Lossos,et al.  A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma , 2011, Proceedings of the National Academy of Sciences.

[155]  B. Sander,et al.  Impact of TP53 mutation and 17p deletion in mantle cell lymphoma , 2011, Leukemia.

[156]  A. Chott,et al.  Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma , 2011, Haematologica.

[157]  C. Pott.  Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. , 2011, Seminars in hematology.

[158]  A. Feldman,et al.  Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. , 2011, The Lancet. Oncology.

[159]  John D. Roberts,et al.  Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms , 2011, Clinical Cancer Research.

[160]  A. Nademanee,et al.  Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  Derick R. Peterson,et al.  The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. , 2011, Blood.

[162]  Peter Martin,et al.  Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  R. Gascoyne,et al.  A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) , 2011, Leukemia & lymphoma.

[164]  B. Sander,et al.  High‐resolution genomic screening in mantle cell lymphoma—specific changes correlate with genomic complexity, the proliferation signature and survival , 2011, Genes, chromosomes & cancer.

[165]  R. Martino,et al.  Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience , 2011, Therapeutic advances in hematology.

[166]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[167]  T. Habermann,et al.  A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.

[168]  Dereje D. Jima,et al.  Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. , 2010, Blood.

[169]  E. Epner,et al.  Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma , 2010, Leukemia & lymphoma.

[170]  Michael L. Wang,et al.  PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib , 2010 .

[171]  C. Craddock,et al.  Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[172]  J. Cigudosa,et al.  Mantle cell lymphoma: transcriptional regulation by microRNAs , 2010, Leukemia.

[173]  W. Klapper,et al.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.

[174]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[175]  Tint Lwin,et al.  microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. , 2010, Blood.

[176]  W. Harrington,et al.  BCL6, MUM1, and CD10 Expression in Mantle Cell Lymphoma , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[177]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[178]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[179]  R. Orlowski,et al.  A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies , 2009, Clinical Cancer Research.

[180]  Elin Gustavsson,et al.  Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt’s lymphoma , 2009, Haematologica.

[181]  Michael L. Wang,et al.  Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  L. Peterson,et al.  Immunophenotypic variations in mantle cell lymphoma. , 2009, American journal of clinical pathology.

[183]  H. Prince,et al.  Mantle cell lymphoma with central nervous system involvement: frequency and clinical features , 2009, British journal of haematology.

[184]  M. Eriksson,et al.  Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  A. Rosenwald,et al.  MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. , 2009, Cancer research.

[186]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  I. Lossos,et al.  Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma , 2009, British journal of haematology.

[188]  L. Medeiros,et al.  Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. , 2009, Blood.

[189]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  J. Leonard,et al.  Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  T. Barbui,et al.  High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen , 2009, Bone Marrow Transplantation.

[192]  A. Hagenbeek,et al.  High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients , 2009, British journal of haematology.

[193]  E. Hoster,et al.  Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  N. Callander,et al.  VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network , 2008 .

[195]  M. Sorror,et al.  Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). , 2008 .

[196]  Michael L. Wang,et al.  Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL) , 2008 .

[197]  E. Hoster,et al.  The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial , 2008 .

[198]  M. Stauch,et al.  Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL) , 2008 .

[199]  E. Hoster,et al.  Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma , 2008 .

[200]  G. Salles,et al.  RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA , 2008 .

[201]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[202]  William A Robinson,et al.  Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. , 2008, Blood.

[203]  D. Moore,et al.  Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma , 2008, Cancer.

[204]  R. Fonseca,et al.  Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group , 2008, Cancer.

[205]  H. Pospíšilová,et al.  Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. , 2008, Blood.

[206]  R. Hicks,et al.  [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. , 2008, Clinical lymphoma & myeloma.

[207]  E. Hoster,et al.  European mantle cell lymphoma network: An update on current first line trials , 2008 .

[208]  C. Doglioni,et al.  Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. , 2008, Blood.

[209]  W. Klapper,et al.  Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations , 2008, Haematologica.

[210]  F. Berrino,et al.  Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. , 2008, European journal of cancer.

[211]  W. Klapper,et al.  Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. , 2008, Blood.

[212]  A. Rademaker,et al.  A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long‐term follow‐up in newly diagnosed mantle cell lymphoma , 2008, British journal of haematology.

[213]  L. Mortelmans,et al.  Positron emission tomography in mantle cell lymphoma , 2008, Leukemia & lymphoma.

[214]  Deborah A. Thomas,et al.  Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. , 2007, Clinical lymphoma & myeloma.

[215]  R. Fisher,et al.  A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma. , 2007 .

[216]  A. Rossi,et al.  Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma , 2007 .

[217]  A. Rosenwald,et al.  Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  A. Rosenwald,et al.  Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. , 2007, Blood.

[219]  Adrian Wiestner,et al.  Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. , 2007, Blood.

[220]  G. Schwarzer,et al.  Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.

[221]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[222]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  D. Weisenburger,et al.  Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). , 2006, Blood.

[224]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[225]  S. Dakhil,et al.  Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  A. Hubalewska-Dydejczyk,et al.  90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment. , 2006 .

[227]  N. Schmitz,et al.  Matched Unrelated Donor Stem Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma. A Retrospective Analysis from the EBMT Lymphoma Working Party. , 2006 .

[228]  J. Connors,et al.  Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis. , 2006 .

[229]  J. Szer,et al.  The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma , 2006, Annals of Hematology.

[230]  B. Coiffier,et al.  Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[231]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  A. Salar,et al.  Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic Study , 2006, The American journal of surgical pathology.

[233]  R. Gascoyne,et al.  A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[234]  E. Jaffe,et al.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.

[235]  C. Jones,et al.  Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[236]  D. Weisenburger,et al.  A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. , 2006, Blood.

[237]  R. Advani,et al.  Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  W. Hiddemann,et al.  Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLRG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  A. Zelenetz,et al.  Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[240]  A. Rosenwald,et al.  The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. , 2006, Blood.

[241]  R. Siebert,et al.  Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. , 2006, Blood.

[242]  L. Staudt,et al.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[243]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[244]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[245]  J. Yahalom,et al.  Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). , 2005, International journal of radiation oncology, biology, physics.

[246]  G. Salles,et al.  Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma , 2005, Cancer.

[247]  A. Grillo‐López.  Is rituximab effective as a single agent in mantle-cell lymphoma? , 2005, Nature Clinical Practice Oncology.

[248]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[249]  W. Klapper,et al.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.

[250]  P. Marlton,et al.  Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review , 2005, Leukemia & lymphoma.

[251]  A. Hagemeijer,et al.  Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma , 2005, British journal of haematology.

[252]  J. Seymour,et al.  Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP , 2005, Leukemia & lymphoma.

[253]  A. Rosenwald,et al.  CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. , 2005, Cancer research.

[254]  C. Larsson,et al.  Mantle cell lymphomas with clonal immunoglobulin VH3–21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin VH genes , 2005, Modern Pathology.

[255]  M. Ghielmini,et al.  Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[256]  M. Maris,et al.  Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. , 2004, Blood.

[257]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[258]  A. Ganser,et al.  Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[259]  D. Catovsky,et al.  The Leukemic Presentation of Mantle-cell Lymphoma: Disease Features and Prognostic Factors in 58 Patients , 2004, Leukemia & lymphoma.

[260]  W. Hiddemann,et al.  The role of fludarabine in the treatment of follicular and mantle cell lymphoma , 2004, Cancer.

[261]  A. Tulpule,et al.  Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[262]  R. Stahel,et al.  Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[263]  J. Connors,et al.  Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[264]  R. Champlin,et al.  Long‐term follow‐up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission , 2003, Cancer.

[265]  P. Mclaughlin,et al.  Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[266]  H. Müller-Hermelink,et al.  VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. , 2003, Blood.

[267]  R. Gascoyne,et al.  Limited-stage mantle-cell lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[268]  R. Gascoyne,et al.  Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma. , 2003, Human pathology.

[269]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[270]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[271]  L. Staudt.  Molecular diagnosis of the hematologic cancers. , 2003, The New England journal of medicine.

[272]  M. Raffeld,et al.  Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. , 2003, Blood.

[273]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[274]  P. Mclaughlin,et al.  Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma , 2003, Cancer.

[275]  K. Franssila,et al.  Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. , 2003, European journal of cancer.

[276]  M. Hansmann,et al.  Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. , 2002, European journal of cancer.

[277]  J. Gribben,et al.  Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. , 2002, Experimental hematology.

[278]  S. A. Bush,et al.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. , 2002, Blood.

[279]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[280]  F. Cabanillas,et al.  Mantle-cell lymphoma. , 2001, The Lancet. Oncology.

[281]  B. Nadel,et al.  Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. , 2001, Cancer research.

[282]  T. Habermann,et al.  Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma , 2001, Leukemia & lymphoma.

[283]  R. Gascoyne,et al.  Blastic Mantle Cell Leukemia: An Unusual Presentation of Blastic Mantle Cell Lymphoma , 2000, Modern Pathology.

[284]  H. Kantarjian,et al.  Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[285]  M. James,et al.  Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. , 1999, Blood.

[286]  R. Kanteti,et al.  Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease: a clinical and molecular analysis , 1999, Bone Marrow Transplantation.

[287]  K. Franssila,et al.  Central nervous system involvement in patients with mantle cell lymphoma , 1999, Annals of Hematology.

[288]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[289]  J. Tworek,et al.  Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. , 1998, American journal of clinical pathology.

[290]  P. Cohen,et al.  Bone marrow and peripheral blood involvement in mantle cell lymphoma , 1998, British journal of haematology.

[291]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Cancer.

[292]  J. Gribben,et al.  Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. , 1997, Blood.

[293]  N. Callander,et al.  Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation , 1997, Bone Marrow Transplantation.

[294]  W. Hiddemann,et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.

[295]  E. Schuuring,et al.  Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. , 1996, Blood.

[296]  E. Jaffe,et al.  bcl-1 Rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis , 1996 .

[297]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[298]  G. Inghirami,et al.  Large‐cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome , 1996, British journal of haematology.

[299]  D. Weisenburger,et al.  Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin. , 1996, The American journal of surgical pathology.

[300]  A. López-Guillermo,et al.  CNS involvement in mantle-cell lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[301]  B. Coiffier,et al.  European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL) , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[302]  H. Müller-Hermelink,et al.  The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl‐1 gene and high proliferation indices , 1994, Histopathology.

[303]  S. Poppema,et al.  Small lymphocytic lymphomas with predominant splenomegaly: a comparison of immunophenotypes with cases of predominant lymphadenopathy. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[304]  D. Weisenburger,et al.  Mantle zone lymphoma a clinicopathologic study of 22 cases , 1990, Cancer.

[305]  M. Engelhard,et al.  Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis , 1989, Hematological oncology.

[306]  E. Jaffe,et al.  Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases. , 1989, Journal of clinical pathology.

[307]  F. Alt,et al.  Development of the primary antibody repertoire. , 1987, Science.

[308]  T. Lister,et al.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. , 1983, The American journal of pathology.

[309]  D. Weisenburger,et al.  Mantle‐zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma , 1982, Cancer.

[310]  E. Jaffe,et al.  Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. , 1977, American journal of clinical pathology.

[311]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[312]  Michael L. Wang,et al.  Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[313]  M. Stauch,et al.  Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. , 2016, The Lancet. Oncology.

[314]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[315]  S. Schwartz,et al.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. , 2013, International journal of clinical and experimental pathology.

[316]  Ryan D. Morin,et al.  Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.

[317]  J. Leonard,et al.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[318]  P. Dreger,et al.  Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. , 2008, Biology of Blood and Marrow Transplantation.

[319]  A. López-Guillermo,et al.  Central nervous system involvement in mantle cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[320]  A. Nademanee,et al.  Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[321]  F. Bertoni,et al.  The cellular origin of mantle cell lymphoma. , 2007, The international journal of biochemistry & cell biology.

[322]  M. Bernard,et al.  Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. , 2006, Haematologica.

[323]  Zhe Zhang,et al.  Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[324]  F. Bosch,et al.  Familial lymphoid neoplasms in patients with mantle cell lymphoma. , 2004, Haematologica.

[325]  A. Delmer,et al.  Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. , 2004, Haematologica.

[326]  R. Gascoyne,et al.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[327]  F. Bosch,et al.  ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. , 2002, Blood.

[328]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[329]  A. Pileri,et al.  Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. , 2000, Blood.

[330]  F. Cavalli,et al.  Clonality assessment in blood of patients with mantle cell lymphoma. , 1999, Leukemia & lymphoma.

[331]  L. Baldini,et al.  Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL). , 1998, Haematologica.

[332]  J. Gribben,et al.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[333]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[334]  D. Arber,et al.  Non-Hodgkin's lymphoproliferative disorders involving the spleen. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[335]  Preud'homme,et al.  Serum Ig Abnormalities in Mantle Cell Lymphoma , 1997, Blood.

[336]  T. Molina,et al.  Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'étude des Lymphomes Digestifs. , 1997, Gastroenterology.

[337]  R. Fisher,et al.  Mantle-cell lymphoma: classification and therapeutic implications. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[338]  J. Chan.  Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. , 1996, Seminars in diagnostic pathology.